HomeSectors

Sectors

ResMed Q4 Results: Sales Climb 9%, Margins Slip

Carbonxt Agrees Balance Sheet Restructuring as Kentucky Plant Nears Production

CSL Horizon 2 Clinical Trials Aim to Stretch Plasma

Breaking the Chain: The Race to Decouple US Defense from Chinese Minerals

DroneShield Bags $23.2M European Contracts as Margins Slip

Dexus finishes its $2 billion divestment a year early

ASX Dividend Stocks in 2026: When Cash Fights Back

Woodside Energy Outlook: How High Could Its Share Price Climb in Australia?

CSL Share Price Forecast 2026: UBS Sees Strong Upside for ASX Biotech Leader

Santos Ltd Update: Future Energy Growth Trends in Australia

COLITCO LLP accepts no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. COLITCO LLP or an associate may receive a commission for funds raised.

↑